This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Exact Sciences（EXAS）株式概要
エグザクト・サイエンシズ・コーポレーションは、米国内外でがん検診・診断検査製品を提供している。 詳細
報酬
リスク分析
リスクチェックの結果、EXAS 、リスクは検出されなかった。
EXAS Community Fair Values
Create NarrativeSee what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Exact Sciences Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$104.91 |
| 52週高値 | US$104.98 |
| 52週安値 | US$38.81 |
| ベータ | 1.44 |
| 1ヶ月の変化 | 1.43% |
| 3ヶ月変化 | 3.32% |
| 1年変化 | 129.71% |
| 3年間の変化 | 58.26% |
| 5年間の変化 | -15.16% |
| IPOからの変化 | 611.25% |
最新ニュース
ナラティブ更新 • Mar 16
EXAS: Abbott Deal Expectations And Downgrades Will Shape Event Path Forward
The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81. Analyst Commentary Recent Street research around Exact Sciences has been limited, with one identified change being a downgrade and another reference tied to a broader sector view rather than company specific fundamentals.
ナラティブ更新 • Mar 02
EXAS: Fair Value Reset Will Hinge On Abbott Deal And Margin Delivery
Analysts have trimmed their fair value estimate for Exact Sciences from $116.46 to $112.11. This reflects slightly lower modeled revenue growth, offset by a modestly higher profit margin outlook and a reduced future P/E assumption.ナラティブ更新 • Feb 16
EXAS: Abbott Takeout Price And Downgrades Will Shape Event Path Forward
Analysts have maintained their $105 per share price target for Exact Sciences, with recent research emphasizing the agreed Abbott acquisition price of $105 as the key anchor for valuation and indicating limited expectations for additional upside. Analyst Commentary Recent research around Exact Sciences has shifted sharply toward viewing the agreed US$105 per share Abbott offer as the primary reference point for valuation, with many firms recalibrating their ratings and targets to that level.Recent updates
ナラティブ更新 • Mar 16
EXAS: Abbott Deal Expectations And Downgrades Will Shape Event Path Forward
The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81. Analyst Commentary Recent Street research around Exact Sciences has been limited, with one identified change being a downgrade and another reference tied to a broader sector view rather than company specific fundamentals.ナラティブ更新 • Mar 02
EXAS: Fair Value Reset Will Hinge On Abbott Deal And Margin Delivery
Analysts have trimmed their fair value estimate for Exact Sciences from $116.46 to $112.11. This reflects slightly lower modeled revenue growth, offset by a modestly higher profit margin outlook and a reduced future P/E assumption.ナラティブ更新 • Feb 16
EXAS: Abbott Takeout Price And Downgrades Will Shape Event Path Forward
Analysts have maintained their $105 per share price target for Exact Sciences, with recent research emphasizing the agreed Abbott acquisition price of $105 as the key anchor for valuation and indicating limited expectations for additional upside. Analyst Commentary Recent research around Exact Sciences has shifted sharply toward viewing the agreed US$105 per share Abbott offer as the primary reference point for valuation, with many firms recalibrating their ratings and targets to that level.ナラティブ更新 • Feb 02
EXAS: Takeout Premium And Downgrades Will Frame Upcoming Deal Closure Risk
Analysts made a modest upward adjustment to their fair value estimate for Exact Sciences to $105.81, describing it as largely in line with the $105 per share Abbott takeout price and supported by updated assumptions around discount rate, profit margin, and future P/E in recent research following the wave of rating downgrades tied to the announced acquisition. Analyst Commentary Street research around Exact Sciences has shifted quickly toward treating the shares as a deal proxy after the announced US$105 per share cash offer from Abbott.ナラティブ更新 • Jan 19
EXAS: Abbott Takeover Agreement Will Anchor Upside To Deal Completion
Analysts have lifted their fair value estimate for Exact Sciences from $77.68 to $116.46. This reflects updated assumptions around slightly higher revenue growth, a revised profit margin outlook, a modestly higher discount rate, and a higher future P/E multiple in light of the agreed Abbott takeout price of $105 per share and the cluster of Street targets around that level.
ナラティブ更新 • Jan 04
EXAS: Abbott Deal At $105 Will Define Shares With Balanced Prospects
Analysts have raised their price target on Exact Sciences to approximately $93 from about $48, citing the $105 per share Abbott takeout as validation of higher long term profitability and valuation multiples, despite slightly tempered standalone growth expectations. Analyst Commentary Bearish analysts largely framed the Abbott transaction as crystallizing value and limiting further upside, prompting a wave of rating downgrades to Hold, Neutral, Equal Weight, and Market Perform.ナラティブ更新 • Dec 15
EXAS: Takeout Premium Will Shift Focus To Deal Completion Risk Balancing Upside
Analysts have raised their price targets on Exact Sciences toward the agreed Abbott takeout price of $105 per share. This reflects improved growth and margin expectations alongside the belief that the acquisition premium fairly captures the company’s long term value.ナラティブ更新 • Dec 01
EXAS: Acquisition By Abbott Will Shift Focus Toward Deal Closure And Approval
The analyst price target for Exact Sciences has increased from $82.10 to $103.67 following the announcement of its acquisition by Abbott for $105 per share. Analysts cite the takeover premium and strong strategic rationale as key drivers behind the upward revision.Seeking Alpha • Nov 20
Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know
Summary Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue growth, record Q3 results, and promising new products like CancerGuard but remains unprofitable with fierce competition in cancer screening. Abbott Laboratories seeks to revitalize growth and expand its diagnostics portfolio, betting on Exact Sciences' MCED technology and established products like Cologuard despite high acquisition costs. Maintain Hold ratings on both Exact Sciences and Abbott Laboratories; Exact shareholders benefit from the deal, while Abbott's upside depends on successful integration and MCED market adoption. Read the full article on Seeking Alpha分析記事 • Nov 20
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too
Despite an already strong run, Exact Sciences Corporation ( NASDAQ:EXAS ) shares have been powering on, with a gain of...ナラティブ更新 • Nov 17
EXAS: Revenue Momentum And Expanded Guidance Will Drive Shares Higher
Analysts have raised their price target for Exact Sciences from approximately $70 to $82, citing stronger-than-expected revenue growth, margin expansion, and several upward revisions in expectations following earnings. Analyst Commentary Recent analyst updates reflect growing optimism about Exact Sciences' prospects, particularly in light of strong revenue growth, expanded guidance, and successful execution across its core business lines.ナラティブ更新 • Nov 01
EXAS: Cancer Screening Expansion Will Balance Challenges From Blood Test Data
Analysts have raised their price target for Exact Sciences to $70 from $60, citing continued strength in its core Cologuard franchise as well as expanding opportunities in cancer screening and detection. Analyst Commentary Recent analyst activity for Exact Sciences reflects a dynamic mix of optimism and caution, as the company continues to execute on its core strengths while navigating evolving market expectations.ナラティブ更新 • Oct 18
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have raised their price target for Exact Sciences to approximately $70 from $65, citing strong momentum from new revenue opportunities and increased confidence in long-term growth drivers. Analyst Commentary Recent analyst actions on Exact Sciences reflect notable shifts in sentiment, both positive and cautious, following the company’s latest performance and strategic moves.ナラティブ更新 • Oct 03
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have modestly raised their price target for Exact Sciences, increasing it from $64.01 to $65.38. They cite incremental near-term revenue growth drivers, ongoing margin expansion, and improved cash flow prospects as key reasons for the upward adjustment.ナラティブ更新 • Sep 12
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have modestly raised Exact Sciences’ price target to $64.01, citing renewed optimism from the Freenome deal and Shield V2 data as potential growth catalysts despite near-term skepticism around CRC blood-test data, resulting in only a slight upward revision to fair value. Analyst Commentary Bullish analysts cite the Freenome deal and Shield V2 data as catalysts for renewed Street focus on execution, with multiple near-term revenue growth drivers, continued EBITDA margin expansion, improving cash flow, and possible estimate upside.分析記事 • Sep 08
Exact Sciences Corporation's (NASDAQ:EXAS) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders are no doubt pleased to see that the share price has bounced...ナラティブ更新 • Aug 08
Humana, Centene And Medicare Coverage Will Increase Screening Access
Despite a slight rise in Exact Sciences’ future P/E ratio and a modest decline in its net profit margin, the consensus analyst price target remains unchanged at $64.60. What's in the News Exact Sciences raised full-year 2025 revenue guidance to $3.13–$3.17 billion, up from previous estimates of $3.07–$3.12 billion, reflecting strong business momentum (Key Developments, 2025-08-06).
新しいナラティブ • Apr 27
Cologuard Plus And Oncodetect Will Improve Cancer Screening Outcomes
Cologuard Plus and rescreening efforts are key drivers of revenue growth, bolstered by payer coverage and an increasing pool of eligible individuals.Seeking Alpha • Aug 18
Exact Sciences: Cost Optimization And Product Strength
Summary Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening segment. It raised adjusted EBITDA guidance for 2024, demonstrating confidence in continued sales momentum and profitability. It is likely to suffer from volatility risks as it continues to strike a balance between growth and profitability. The stock is a buy with a potential 27% upside also given the way it is improving its competitive position and leveraging AI for accelerating data analysis. Read the full article on Seeking AlphaSeeking Alpha • Jun 11
Exact Sciences: Still No Reason To Own
Summary We are revisiting oncology testing company Exact Sciences Corporation today for the first time in nearly a year and a half. The shares have been cut by more than half since last summer, despite revenue growth in the low teens and strong support from the analyst firm community. Is it time to buy the dip? An updated analysis around Exact Sciences follows in the paragraphs below. Read the full article on Seeking Alpha株主還元
| EXAS | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.9% | 1.5% | 1.5% |
| 1Y | 129.7% | 41.7% | 25.5% |
業界別リターン: EXAS過去 1 年間で41.7 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: EXAS過去 1 年間で25.5 % の収益を上げたUS市場を上回りました。
価格変動
| EXAS volatility | |
|---|---|
| EXAS Average Weekly Movement | 0.5% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: EXAS 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: EXASの 週次ボラティリティ は、過去 1 年間で6%から0%に減少しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1995 | 7,150 | n/a | www.exactsciences.com |
エグザクト・サイエンシズ・コーポレーション（Exact Sciences Corporation）は、米国および海外でがんスクリーニング検査および診断検査製品を提供している。大腸がんやその前がんに関連するDNAやヘモグロビンのバイオマーカーを検出する非侵襲的な便ベースのDNAスクリーニング検査であるCologuard、Cologuard Plus Tests、Cancerguard Tests、Genetic Testingを提供している。また、オンコタイプDX乳房再発スコア検査、オンコタイプDX乳房DCISスコア検査、オンコタイプDX大腸再発スコア検査、進行がん、転移性がん、難治性がん、再発・再燃がん患者を対象とした腫瘍プロファイリング用Oncodetect検査、OncoExTra検査、遺伝性のがんリスクを把握するための遺伝性がん検査であるRiskguard検査も提供している。同社のパイプラインは、リスク評価、スクリーニング、予防、早期診断、アジュバントおよび/またはネオアジュバント治療、転移性疾患の治療選択、再発モニタリングなどのスクリーニングおよび診断製品の開発に重点を置いている。同社は、MAYO医学教育研究財団、ジョンズ・ホプキンス大学、およびFreenome Holdings, Inc.とライセンス契約を結んでいる。エグザクト・サイエンシズ・コーポレーションは1995年に設立され、ウィスコンシン州マディソンに本社を置いている。2026年3月23日現在、Exact Sciences CorporationはAbbott Laboratoriesの子会社として運営されている。
Exact Sciences Corporation 基礎のまとめ
| EXAS 基礎統計学 | |
|---|---|
| 時価総額 | US$20.03b |
| 収益（TTM） | -US$207.95m |
| 売上高(TTM) | US$3.25b |
6.2x
P/Sレシオ-96.3x
PER（株価収益率EXAS は割高か？
公正価値と評価分析を参照収益と収入
| EXAS 損益計算書（TTM） | |
|---|---|
| 収益 | US$3.25b |
| 売上原価 | US$984.15m |
| 売上総利益 | US$2.26b |
| その他の費用 | US$2.47b |
| 収益 | -US$207.95m |
直近の収益報告
Dec 31, 2025
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.09 |
| グロス・マージン | 69.69% |
| 純利益率 | -6.40% |
| 有利子負債／自己資本比率 | 96.9% |
EXAS の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/03/24 23:12 |
| 終値 | 2026/03/20 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Exact Sciences Corporation 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27
| アナリスト | 機関 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |